Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Beam Therapeutics's enterprise value was $1.57B on Nov 11, 2026, against $1.47B a year earlier. Over the last 5 years it ranged from $391.82M to $4.46B, with a median of $1.35B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.57B | -8.4% |
| 2025 | Dec 31, 2025 | $1.71B | +52.4% |
| 2024 | Dec 31, 2024 | $1.12B | -3.4% |
| 2023 | Dec 29, 2023 | $1.16B | -29.9% |
| 2022 | Dec 30, 2022 | $1.66B | -62.9% |
| 2021 | Dec 31, 2021 | $4.46B | +14.0% |
| 2020 | Dec 31, 2020 | $3.92B | – |
See a number that looks wrong?